LACTULOSE SOLUTION, USP

Manufacturer
VistaPharm, LLC
Effective date
2024-12-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
legacy-cache
Hydrated at
2026-08-01 20:47:28

Label at a glance#

ProductLACTULOSE
Active ingredientLACTULOSE
Label structure13 sections

Indications and uses

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Dosage and administration

The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement. Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Lactulose is a synthetic disaccharide in solution form for oral administration. Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g of other sugars). Also contains FD&C Yellow No. 6, purified water, USP and wild cherry flavoring. A minimal quantity of sodium hydroxide, NF is used to adjust pH when necessary. The pH range is 2.5 to 6.5.

Lactulose is a colonic acidifier which promotes laxation.The chemical name for lactulose is 4-O-β-D-galactopyranosyl-D-fructofuranose. It has the following structural formula:

Chemical Structure
Chemical Structure

C12H22O11

The molecular weight is 342.30. It is freely soluble in water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Lactulose is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce the desired bowel movement.

Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Since lactulose solution contains galactose (less than 1.6 g/15 mL), it is contraindicated in patients who require a low galactose diet.

WARNINGS

WARNINGS SECTION

A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO2 as an additional safeguard may be pursued but is considered to be a redundant measure.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL) it should be used with caution in diabetics.

Information for Patients

INFORMATION FOR PATIENTS SECTION

In the event that an unusual diarrheal condition occurs, contact your physician.

Laboratory Tests

LABORATORY TESTS SECTION

Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

Drug Interactions

DRUG INTERACTIONS SECTION

Results of preliminary studies in humans and rats suggest that non-absorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.

There are no known animal data on long-term potential for mutagenicity.

Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.

In studies of mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy category B

SPL UNCLASSIFIED SECTION

Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Precise frequency data are not available.

Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

Nausea and vomiting have been reported.

OVERDOSAGE

OVERDOSAGE SECTION

Signs And Symptoms

SPL UNCLASSIFIED SECTION

There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

Oral LD50

SPL UNCLASSIFIED SECTION

The acute oral LD50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.

Dialysis

SPL UNCLASSIFIED SECTION

Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.

HOW SUPPLIED

HOW SUPPLIED SECTION

Lactulose Solution is available as a cherry-flavored solution, 10 g/15 mL, supplied as follows:

NDC 66689-039-01: 15 mL unit dose cup.

NDC 66689-039-50: Case contains 50 unit dose cups of 15 mL (66689-039-01), packaged in 5 trays of 10 unit dose cups each.

Lactulose Solution is available as a cherry-flavored solution, 20 g/30 mL, supplied as follows:

NDC 66689-038-01: 30 mL unit dose cup.

NDC 66689-038-50: Case contains 50 unit dose cups of 30 mL (66689-038-01), packaged in 5 trays of 10 unit dose cups each.

NDC 66689-038-99: Case contains 100 unit dose cups of 30 mL (66689-038-01), packaged in 10 trays of 10 unit dose cups each.

Lactulose Solution contains lactulose 667 mg/mL (10 g/15 mL).

When ordering this product, include the product code number or NDC in the description.

Storage

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Avoid subfreezing temperatures.

Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action. Prolonged exposure to temperatures above 86°F (30°C) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use.

Prolonged exposure to freezing temperatures may cause change to a semi-solid, too viscous to pour. Viscosity will return to normal upon warming to room temperature.

Dispense in a tight, light-resistant container as defined in the USP.

SPL UNCLASSIFIED SECTION

Rx Only. Keep this and all drugs out of the reach of children.

Manufactured by:
VistaPharm

Largo, FL 33771

VP2051R2
10/19

PRINCIPAL DISPLAY PANEL - 20 g/30 mL cup label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Xact DOSE™

LACTULOSE
SOLUTION, USP
20 g/30 mL

NDC 66689-038-01

INDICATIONS AND DOSAGE: For the
treatment of constipation. See insert.
Avoid subfreezing temperatures.
Store at 20°–25°C (68°–77°F)
[See USP CONTROLLED RM TEMP]

Rx Only     This cup delivers 30 mL    VP2050

Manufactured by VistaPharm, Inc.
Largo, FL 33771

Principal Display Panel - 20 g/30 mL cup label
Principal Display Panel - 20 g/30 mL cup label

PRINCIPAL DISPLAY PANEL - 10 g/15 mL cup label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Xact DOSE™

LACTULOSE
SOLUTION, USP
10 g/15 mL

NDC 66689-039-01

INDICATIONS AND DOSAGE: For the
treatment of constipation. See insert.
Avoid subfreezing temperatures.
Store at 20°–25°C (68°–77°F)
[See USP CONTROLLED RM TEMP]

Rx Only     This cup delivers 15 mL    VP2049

Manufactured by VistaPharm, Inc.
Largo, FL 33771

Principal Display Panel - 10 g/15 mL cup label
Principal Display Panel - 10 g/15 mL cup label

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
66689-038-502024-01-30C16284748780-11030e365-4e41-111a-e063-dadaa90a10e2LACTULOSE SOLUTION, USP
66689-038-992024-01-30C16284748780-11030e365-4e41-111a-e063-dadaa90a10e2LACTULOSE SOLUTION, USP
66689-039-502024-01-30C16284748780-11030e365-4e41-111a-e063-dadaa90a10e2LACTULOSE SOLUTION, USP

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
66689-038LACTULOSE SOLUTION [VISTAPHARM, LLC]7Legacy NDC20241207_7016bd71-c667-46fc-8c56-5023682e8bbe.zip
66689-039LACTULOSE SOLUTION [VISTAPHARM, LLC]7Legacy NDC20241207_7016bd71-c667-46fc-8c56-5023682e8bbe.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
66689-039-01ML - Milliliter66689-0392b7f13ad-5317-4e81-aa70-ce4a513e340f12012-07-24
66689-039-50ML - Milliliter66689-039e7f4dd82-a72b-422a-b7b4-0d4309fdcece12012-07-24
66689-038-01ML - Milliliter66689-0381c0bf06a-e967-432c-ae90-bbd58d3bc5d112012-07-24
66689-038-50ML - Milliliter66689-0385dc61d02-232e-4425-a8bf-47fc92e7c82312012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
LACTULOSEACTIVE INGREDIENT9U7D5QH5AE2
LACTULOSEACTIVE MOIETY9U7D5QH5AE2
FD&C YELLOW NO. 6INACTIVE INGREDIENTH77VEI93A82
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I2
WATERINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
66689-03966689-039-01, 66689-039-50
66689-03866689-038-01, 66689-038-50, 66689-038-99

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 208 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / SUBCUTANEOUSNAExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8TABLET, CHEWABLE / ORAL0.41 mgExact identifier — unii candidate
34 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8CAPSULE, DELAYED RELEASE / ORAL0.02 mgExact identifier — unii candidate
34 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / OPHTHALMIC6 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8LOTION / TOPICALNAExact identifier — unii candidate
34 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED PELLETS / ORAL0.01 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8CAPSULE, COATED / ORAL0.03 mgExact identifier — unii candidate
34 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / ORAL2 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTABLE, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRASPINALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / VAGINAL20 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, DELAYED RELEASE / ORAL0.25 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8SYRUP / ORAL4 mg/5mlExact identifier — unii candidate
34 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / IONTOPHORESISADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IOINTMENT, AUGMENTED / TOPICAL0.11 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISHAMPOO / TOPICAL3 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IOINTMENT / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISYRUP / ORAL71 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8LIQUID / ORAL0.2 mg/1mlExact identifier — unii candidate
34 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILOTION, AUGMENTED / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / URETERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / RETROBULBARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / TOPICAL39 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, FILM COATED / ORAL8 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SUBCUTANEOUS31.45 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, DELAYED RELEASE / ORAL4 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVESICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED / ORAL0.08 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SUBMUCOSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IDROPS / OPHTHALMICNAExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAMUSCULAR78 mgExact identifier — unii candidate
174 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074138-001LACTULOSELACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-3084e616aacf4f…
2026-08-18 06:07:402026-07A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-308072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-305c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-305d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-304b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-3074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-3087673890dc5c…
2021-03-12 10:30 UTC2021-03A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-305aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-308869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-303f01610625f2…
2019-09-15 20:21 UTC2019-09A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30b00525d2431f…
2019-07-19 19:46 UTC2019-07A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-301c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-30a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074138-001LACTULOSE10GM/15MLSOLUTION / ORAL1992-09-309b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-303f0d92c62455…
2023-05-13 08:27 UTC2023-05A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30053a50430f4f…
2023-01-26 05:58 UTC2023-01A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-303bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-303a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074138-001LACTULOSE10GM/15MLSOLUTION / ORALAA1992-09-30f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074138-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074138-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074138-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074138-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074138-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074138-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074138-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A074138-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074138-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074138-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074138-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A074138-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A074138-001AA1ea99ee380514…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074138-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074138-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A074138-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A074138-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074138-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074138-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A074138-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A074138-001AA1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
bf46fee5-e970-4f20-b389-958e5d55c28e7016bd71-c667-46fc-8c56-5023682e8bbe2024-12-05Warnings, Adverse reactionsExact identifier
spl id: bf46fee5-e970-4f20-b389-958e5d55c28e
spl set id: 7016bd71-c667-46fc-8c56-5023682e8bbe

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.